Related Experiment Video

Updated: May 17, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]

N V Furman, L E Kuvshinova, Ia P Dovgalevskiĭ

    Kardiologiia
    |October 27, 2012
    PubMed

    Insights

    This study explores using dabigatran, a novel anticoagulant, alongside electrical cardioversion for atrial fibrillation patients. It highlights a successful case of left ventricular thrombus lysis during dabigatran treatment.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Atrial fibrillation (AF) poses a risk of thromboembolism.
    • Electrical cardioversion is a common treatment for AF.
    • Anticoagulation is crucial during cardioversion, but optimal agents are debated.

    Observation:

    • The study investigated the use of dabigatran, a direct thrombin inhibitor, in patients undergoing electrical cardioversion for AF.
    • A specific case demonstrated successful thrombus resolution within the left ventricular cavity during dabigatran therapy.

    Findings:

    • Dabigatran appears feasible for anticoagulation during electrical cardioversion in AF patients.
    • The data suggests dabigatran may facilitate thrombus lysis, even in complex cases like left ventricular thrombus.

    Implications:

    • Dabigatran offers a potential alternative anticoagulant for AF management and cardioversion.
    • Further research could validate dabigatran's efficacy and safety in this context, potentially improving patient outcomes.

    More Related Videos

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

    Published on: May 26, 2015

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

    Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...